Want to see AU:RAC full AI Analyst Report?
Top Page
Race Oncology Ltd.
(Sydney:RAC)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$2.00
â–¼(-5.66% Downside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance—FY2026 revenue dropping to zero, continued losses, and ongoing cash burn—despite the benefit of a debt-free balance sheet. Technical indicators add moderate support in the short term (price above 20/50DMA and positive MACD), but the longer-term trend remains soft. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Debt-free balance sheet
A debt-free capital structure reduces solvency pressure and avoids mandatory interest or principal payments while the company funds clinical development. This provides greater flexibility to allocate capital, manage volatility, and pursue its oncology program without the additional constraint of financial leverage.
Negative Factors
Revenue collapsed to zero
A return to zero annual revenue represents a major break in operating momentum and leaves the business without demonstrated recurring commercial income in FY2026. This weakens internal funding capacity and makes future progress more dependent on successfully rebuilding revenue from its development-stage operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure reduces solvency pressure and avoids mandatory interest or principal payments while the company funds clinical development. This provides greater flexibility to allocate capital, manage volatility, and pursue its oncology program without the additional constraint of financial leverage.
Read all positive factors
Race Oncology Ltd. (RAC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$378.41M
Dividend YieldN/A
Average Volume (3M)81.61K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue GrowthN/A
EPS Growth-125.09%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding196,068,940
10 Day Avg. Volume70,502
30 Day Avg. Volume81,608
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)10.91
Price to Sales (P/S)0.00
P/FCF Ratio-48.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Race Oncology Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated pr...
How the Company Makes Money
null...
Race Oncology Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 6.04M | 4.00M | 3.13M | 707.81K |
| Gross Profit | -281.31K | 5.41M | 2.22M | -281.20K | 426.61K |
| EBITDA | -12.15M | -4.43M | -14.20M | -12.78M | -11.63M |
| Net Income | -11.09M | -4.79M | -13.82M | -9.92M | -11.20M |
Balance Sheet | |||||
| Total Assets | 38.09M | 17.49M | 20.23M | 26.64M | 37.52M |
| Cash, Cash Equivalents and Short-Term Investments | 34.29M | 13.67M | 17.19M | 21.52M | 33.54M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.64M | 1.48M | 1.92M | 1.15M | 1.42M |
| Stockholders Equity | 36.45M | 16.01M | 18.31M | 25.49M | 36.11M |
Cash Flow | |||||
| Free Cash Flow | -8.25M | -4.57M | -9.55M | -10.65M | -6.26M |
| Operating Cash Flow | -8.25M | -4.57M | -9.55M | -10.65M | -6.26M |
| Investing Cash Flow | -3.14K | 0.00 | 0.00 | 7.90M | 0.00 |
| Financing Cash Flow | 28.87M | 1.06M | 5.21M | -1.28M | 30.51M |
Race Oncology Ltd. Technical Analysis
Negative
2.12
Price Trends
2.05
Negative
2.19
Negative
2.39
Negative
Market Momentum
-0.05
Positive
36.62
Neutral
23.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RAC, the sentiment is Negative. The current price of 2.12 is above the 20-day moving average (MA) of 1.99, above the 50-day MA of 2.05, and below the 200-day MA of 2.39, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.62 is Neutral, neither overbought nor oversold. The STOCH value of 23.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RAC.
Race Oncology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$5.29B | 115.77 | 7.11% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$378.41M | -29.08 | -36.95% | ― | ― | -125.09% | |
45 Neutral | AU$779.74M | -7.07 | -51.15% | ― | ― | -44.83% | |
43 Neutral | AU$45.70M | -0.58 | -98.86% | ― | ― | -27.73% | |
42 Neutral | AU$28.27M | -0.32 | -144.24% | ― | -23.82% | 12.36% | |
41 Neutral | AU$23.60M | -0.13 | -414.10% | ― | ― | -2.15% |
* Healthcare Sector Average
AU:RAC
Race Oncology Ltd.
1.86
-2.16
-53.74%
AU:IMU
Imugene
0.04
-0.36
-89.88%
AU:IMM
Immutep Ltd
0.03
-0.25
-89.12%
AU:TLX
Telix Pharmaceuticals
15.41
0.24
1.58%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.02
-3.13
-60.78%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.03
-72.22%
Race Oncology Ltd. Corporate Events
Racura Oncology Sets AGM Date and Deadline for Director Nominations
Oct 4, 2026
Racura Oncology has scheduled its Annual General Meeting for 12:00 pm AEDT on 23 November 2026 at the State Library of New South Wales in Sydney. The meeting will include the re-election and appointment of directors, with written nominations for b...
Race Oncology director Daniel Tillett lifts indirect shareholding
Sep 29, 2026
Race Oncology director Daniel Tillett has increased his indirect shareholding in the company through Nucleics Pty Ltd, where he is the sole director and shareholder. The on-market purchase of 23,000 fully paid ordinary shares on 24 and 25 Septembe...
Racura Oncology CEO Restructures Shareholdings With No Change in Overall Stake
Sep 22, 2026
Racura Oncology has disclosed a change in CEO Dr Daniel Tillett’s shareholding structure that involves the on-market sale of personally held RAC shares and the corresponding on-market purchase of RAC shares by Nucleics Pty Ltd, a company sol...
Racura Oncology Data Boosts MYC-Targeted Cancer Program and IP Position
Sep 7, 2026
Racura Oncology will present new preclinical data on its RC220 program at the 2026 Frontiers in Cancer Science Conference in Singapore, in partnership with the American Association for Cancer Research. The poster details how the (E,E)-bisantrene i...
Racura Oncology to Host Adelaide Investor Briefing on Clinical Pipeline
Sep 4, 2026
Racura Oncology Ltd has invited investors to a briefing in Adelaide on 30 September 2026, where Managing Director and CEO Dr Daniel Tillett will provide updates on the company’s clinical programs. The event aims to give existing and prospect...
Racura Oncology Issues New Long-Dated Employee Options
Sep 1, 2026
Racura Oncology Ltd has issued 1,579,963 unquoted options under its employee incentive scheme, each exercisable at $3.05 and expiring on 30 June 2030. These options, which are subject to transfer restrictions and will not be quoted on the ASX unti...
Racura Oncology Opens Korean Sites for RC220 Cardioprotective Cancer Trial
Aug 31, 2026
Racura Oncology has opened its first Korean site at Ewha Womans University Seoul Hospital for patient enrolment in the CPACS Phase 1 trial of RC220 with doxorubicin in advanced solid tumours. Additional sites at Severance Hospital and Samsung Medi...
Racura Oncology details strengthened corporate governance framework
Aug 25, 2026
Racura Oncology Ltd has formally outlined its corporate governance framework, confirming that its board of directors is responsible for overseeing the company’s operations on behalf of shareholders and for maintaining high standards of accou...
Race Oncology lodges ASX corporate governance statement for FY26
Aug 25, 2026
Race Oncology Ltd. has filed its corporate governance statement and Appendix 4G with the ASX for the financial year ended 30 June 2026, providing a centralised key to its governance disclosures. The submission confirms that the statement is curren...
Racura Oncology posts deeper annual loss but lifts net asset backing
Aug 25, 2026
Racura Oncology Ltd, formerly known as Race Oncology Limited, reported a sharp deterioration in its financial performance for the year ended 30 June 2026, with revenue from ordinary activities falling 22.2% to $613,291. The loss after tax attribut...
Racura Oncology CEO to Spotlight Phase 3 Cancer Programs at TechKnow Invest Conference
Jul 29, 2026
Racura Oncology Ltd, an ASX-listed Phase 3 biopharmaceutical company, is developing its lead anticancer agent (E,E)-bisantrene through the proprietary RC220 formulation to treat MYC-driven cancers, including acute myeloid leukaemia and EGFR-mutate...
Racura Advances HARNESS-1 Trial After Safe First-Patient Treatment With RC220 Combo
Jul 28, 2026
Racura Oncology reported that the first patient in its HARNESS-1 Phase 1 trial has been safely treated with RC220 at 50 mg/m2 in combination with daily osimertinib, with no dose-limiting toxicities or treatment-related safety concerns observed dur...
Race Oncology Options Expire, Slightly Tightening Capital Structure
Jul 12, 2026
Race Oncology Ltd has announced the expiry of 270,000 options with an exercise price of $4.76, which lapsed unexercised on 12 July 2026. The cessation of these securities marginally reduces the company’s potential future share dilution, slig...
Racura to Present RC220 Cardio-Oncology Phase 1 Data at 2026 Global Summit
Jul 9, 2026
Racura Oncology will present new clinical data from its ongoing CPACS Phase 1 trial of RC220 in combination with doxorubicin at the 2026 Global Cardio-Oncology Summit in Williamsburg, Virginia. The company aims to showcase RC220’s potential ...
Racura Oncology to Spotlight RC220 Pipeline at New Zealand Investor Events
Jul 6, 2026
Racura Oncology will host an investor briefing in Auckland, New Zealand, on 5 August 2026, where Executive Chair Dr Peter Smith will update shareholders on the company’s strategy and the rapid advancement of its RC220 program across three ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.